Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Ujiki

Surgery Evanston, IL Medical Doctor

NPI 1598923047 CMS profile 118091

2650 Ridge Ave, Walgreen Bldg, Suite 2507, Evanston, IL 60201

Open in the dashboard

General payments

$276,208

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$473,207 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Michael Ujiki of Evanston, IL is reported in the CMS Open Payments database as having received $276,208 across 285 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $473,207 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,212 63
2024 General $53,237 57
2023 General $26,242 40
2022 General $25,219 32
2021 General $19,130 13
2020 General $23,882 12
2019 General $77,287 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Ujiki
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Michael Ujiki were reported at $51,212. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Michael Ujiki Surgery median Middle half National median
2019 $77,287 $253 $82–$1,521 $163
2020 $23,882 $131 $40–$706 $114
2021 $19,130 $168 $50–$904 $132
2022 $25,219 $224 $76–$1,218 $149
2023 $26,242 $253 $82–$1,255 $160
2024 $53,237 $279 $90–$1,381 $164
2025 $51,212 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $148,416 126 payments
  2. W. L. Gore & Associates, Inc. $47,065 50 payments
  3. Olympus America Inc. $31,033 39 payments
  4. Medtronic, Inc. $15,631 30 payments
  5. Covidien LP $12,546 18 payments
  6. Apollo Endosurgery US Inc $9,622 10 payments
  7. Olympus Corporation of the Americas $9,555 2 payments
  8. ERBE USA Inc $1,008 2 payments
  9. Cook Incorporated $850 2 payments
  10. Ethicon US, LLC $193 3 payments
  11. Other $291 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $151,190 62 payments
  2. Consulting Fee $85,386 51 payments
  3. Honoraria $19,110 4 payments
  4. Travel and Lodging $13,049 58 payments
  5. Food and Beverage $7,473 110 payments
Products named General payments · program years 2019–2025
  1. RESOLUTION CLIP $46,453 20 payments
  2. GORE ENFORM Preperitoneal Biomaterial $26,998 32 payments
  3. GORE BIO-A Tissue Reinforcement $24,618 26 payments
  4. SpyGlass Discover $22,720 25 payments
  5. ORBERA Intragastric Balloon System $18,608 7 payments
  6. BIO-A Tissue Reinforcement $13,874 5 payments
  7. GORE SYNECOR Biomaterial $12,833 9 payments
  8. GORE DUALMESH Biomaterial $11,358 8 payments
  9. SPYGLASS $11,000 2 payments
  10. 4K Cable 3.0M $10,967 10 payments
  11. Other $108,500 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

240

Median for General Surgery: 59

Drug cost

$4,255

Median for General Surgery: $393

Branded share of claims

14.6%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 112 $2,515
Famotidine Generic 39 $792
Esomeprazole Magnesium Generic 43 $635
Ondansetron Odt Ondansetron Brand 35 $253
Prochlorperazine Maleate Generic 11 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$146,576

Medicare's payments for the services billed

Medicare patients

334

Average age 75

Services billed

658

196 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 58%
Ischemic heart disease 29%
Diabetes 27%
Depression 27%
Chronic kidney disease 23%
Osteoporosis 23%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record